Feature Arrivo developing novel medicines to target hard-to-treat diseases at their source Closely held Arrivo BioVentures is developing novel, first-in-class medicines that target the underlying causes of diseases with high unmet need, aiming to achieve meaningful patient outcomes that extend and improve the... June 10, 2025